Ken Griffin Ocugen, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$0.98 - $1.95 $32,242 - $64,155	-32,900 Reduced 20.04%	131,300 $129,000
Q2 2024 Aug 14, 2024	SELL	$1.18 - $1.98 $109,740 - $184,140	-93,000 Reduced 36.16%	164,200 $254,000
Q1 2024 May 15, 2024	BUY	$0.5 - $1.83 $89,950 - $329,217	179,900 Added 232.73%	257,200 $421,000
Q4 2023 Feb 14, 2024	BUY	$0.36 - $0.57 $864 - $1,367	2,400 Added 3.2%	77,300 $44,000
Q3 2023 Nov 14, 2023	SELL	$0.4 - $0.62 $41,400 - $64,170	-103,500 Reduced 58.02%	74,900 $29,000
Q2 2023 Aug 14, 2023	SELL	$0.45 - $0.88 $79,020 - $154,528	-175,600 Reduced 49.6%	178,400 $96,000
Q1 2023 May 15, 2023	BUY	$0.82 - $1.33 $46,740 - $75,810	57,000 Added 19.19%	354,000 $300,000
Q4 2022 Feb 14, 2023	BUY	$1.11 - $1.87 $134,421 - $226,457	121,100 Added 68.85%	297,000 $386,000
Q3 2022 Nov 14, 2022	SELL	$1.75 - $3.1 $94,150 - $166,780	-53,800 Reduced 23.42%	175,900 $313,000

125

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $204M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.